Financial report for the interval 1 January 2022 to 30 September 2022
- Operating revenue increased by 28% in Danish kroner and by 14% at fixed change charges (CER) to DKK 57.7 billion.
- Sales in North America Operations increased by 37% in Danish kroner (22% at CER), and sales in International Operations increased by 16% in Danish kroner (11% at CER).
- Sales inside Diabetes and Obesity care increased by 29% in Danish kroner to DKK 113.2 billion (18% at CER), primarily pushed by GLP-1 diabetes sales progress of 59% in Danish kroner (44% at CER). Rare illness sales increased by 8% measured in Danish kroner (2% at CER).
- Obesity care sales grew by 91% in Danish Kroner (75% at CER). Novo Nordisk expects to make all Wegovy® dose strengths obtainable in the US in direction of the tip of 2022.
- Within R&D, Novo Nordisk efficiently accomplished a part 2 trial with CagriSema in individuals with sort 2 diabetes and the final part 3a trial with once-weekly insulin icodec.
- For the 2022 outlook, sales progress is now anticipated to be 14-17% at CER and working revenue progress is now anticipated to be 13-16% at CER. Sales and working revenue progress reported in Danish kroner are actually anticipated to be 10 and 15 share factors greater than at CER, respectively.
| PROFIT AND LOSS | 9M 2022 | 9M 2021 | Growth as reported |
Growth at CER* |
| DKK million | ||||
| Net sales | 128,862 | 102,467 | 26% | 16% |
| Operating revenue | 57,722 | 45,010 | 28% | 14% |
| Net revenue | 41,933 | 36,865 | 14% | N/A |
| Diluted earnings per share (in DKK) | 18.42 | 15.98 | 15% | N/A |
| * CER: Constant change charges (common 2021). |
Lars Fruergaard Jørgensen, president and CEO: “We are very pleased with the sales growth in the first nine months of 2022 which has enabled us to raise the outlook for the full year. The growth is driven by increasing demand for GLP-1-based diabetes treatments, especially Ozempic®. Within R&D, the encouraging phase 2 data with CagriSema in type 2 diabetes and the successful completion of the phase 3 programme for once-weekly insulin icodec support our aspiration of further raising the innovation bar for diabetes treatments.”
On 2 November 2022 at 13.00 CET, comparable to 08.00 pm EDT, an earnings name might be held. Investors will be capable to pay attention in by way of a hyperlink on novonordisk.com, which could be discovered beneath ‘Investors’.
| Contacts for additional info | |
| Media: | |
| Ambre Brown Morley
+45 3079 9289 |
Natalia Salomao Abrahao (US)
+1 848 304 1027 |
| Investors: | |
| Daniel Muusmann Bohsen
+45 3075 2175
|
David Heiberg Landsted
+45 3077 6915
|
| Jacob Martin Wiborg Rode
+45 3075 5956
|
Mark Joseph Root (US)
+1 848 213 3219
|
Company announcement No 79 / 2022
